Rani Therapeutics Holdings, Inc.
RANI
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.85% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.85% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 58.85% | -- | -- | -- | -- |
| SG&A Expenses | -17.57% | -17.27% | -14.28% | -11.51% | -9.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.11% | -18.48% | -19.16% | -23.32% | -23.40% |
| Operating Income | 22.76% | 20.80% | 21.24% | 25.21% | 24.96% |
| Income Before Tax | 27.63% | 13.33% | 13.42% | 17.15% | 16.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.63% | 13.33% | 13.42% | 17.15% | 16.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -57.55% | -27.91% | -24.13% | -24.44% | -21.66% |
| Net Income | 1.15% | -0.52% | 2.93% | 9.92% | 11.63% |
| EBIT | 22.76% | 20.80% | 21.24% | 25.21% | 24.96% |
| EBITDA | 22.98% | 21.19% | 21.71% | 25.80% | 25.59% |
| EPS Basic | 44.37% | 25.08% | 22.94% | 23.58% | 20.86% |
| Normalized Basic EPS | -1.87% | 23.27% | 22.94% | 28.20% | 29.64% |
| EPS Diluted | 37.68% | 25.08% | 22.94% | 23.58% | 20.86% |
| Normalized Diluted EPS | -1.87% | 23.27% | 22.94% | 28.20% | 29.64% |
| Average Basic Shares Outstanding | 131.45% | 39.24% | 26.68% | 17.95% | 11.61% |
| Average Diluted Shares Outstanding | 131.45% | 39.24% | 26.68% | 17.95% | 11.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |